The mRNA synthesis and manufacturing market's potential lies in the increasing demand for mRNA therapeutics and vaccines, driven by COVID-19 successes. Opportunities include mRNA custom synthesis and ...

Serious but unacknowledged adverse events from COVID-19 vaccines occurred in the artificially foreshortened Pfizer/BioTech and Moderna trials, write Jeyanthi Kunadhasen, M.D., and Corinne A. Michels, ...

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, ...

A messenger RNA therapy that instructs the body to produce a bacteria-killing 'peptibody' has shown early success in mouse ...

RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...

Vaccinated adults had a 74 percent lower risk of dying from COVID-19—and a 25 percent lower risk of dying, period.

Even supporters of mRNA vaccination against COVID-19 might be surprised at just how much higher death rates are among the ...

Researchers tested mRNA lipid nanoparticles that help muscles produce toxin targeting antibodies * The approach showed ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in ...

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

An internal memo written by the Food and Drug Administration’s top vaccine regulator offers a concerning glimpse into the future of vaccine regulation in the US — and could have profound implications ...